A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2016
At a glance
- Drugs Eribulin (Primary) ; Cyclophosphamide; Docetaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 03 Oct 2016 Status changed from active, no longer recruiting to completed.
- 15 Jul 2016 Planned End Date changed from 1 Mar 2016 to 1 Sep 2016.
- 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium